Welcome to our dedicated page for Bimi International Medical news (Ticker: BIMI), a resource for investors and traders seeking the latest updates and insights on Bimi International Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bimi International Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bimi International Medical's position in the market.
BOQI International Medical Inc. (NASDAQ: BIMI) announced its plan to acquire Chongqing Shanfeng Zhiyuan Biotechnology Co., Ltd. via a Memorandum of Understanding (MOU). Chongqing Shanfeng Zhiyuan specializes in medical devices, disinfection supplies, and cosmetics, operating from a facility of 18,298 sq. ft. with 51 employees. The acquisition aims to enhance BIMI's market presence in Southwest China and is expected to be finalized within 1-2 months, pending regulatory approvals. The purchase price will be determined based on a third-party appraisal of Chongqing Shanfeng Zhiyuan's fair market value.
BOQI International Medical Inc. (NASDAQ: BIMI) reported financial results for FY 2019, marking a significant shift towards healthcare after acquiring Boqi Zhengji. Revenues were $157,978, a substantial increase from $0 in 2018, reflecting operations from the acquisition. The net loss decreased by 74% to $4,452,279, compared to $16,999,794 in 2018. Total operating expenses surged by 637% to $1,566,938. However, liquidity concerns persist, with cash of $36,674 and accumulated deficits raising doubts about the company's sustainability. The plan to dispose of the legacy energy business was also initiated.